Andres Bermudez Caba
Pulmonary Disease · Coto Laurel, PRNPI 1164525705
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,697 and has fallen 53.0% since, to $797 in 2025.
Across 76 payments — averaging $72.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- United Therapeutics Corporation$748
- AstraZeneca$620
- Boehringer Ingelheim$605
- Merck$374
- Bayer$308
- plus $2K from 12 others
What the payments were for
- Food & beverage$5,44299%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 17 | $1,210 |
| United Therapeutics Corporation | 7 | $748 |
| AstraZeneca | 8 | $620 |
| Boehringer Ingelheim | 10 | $605 |
| Merck | 5 | $374 |
| Bayer | 3 | $308 |
| Johnson & Johnson | 7 | $268 |
| Mallinckrodt Hospital Products Inc. | 2 | $220 |
| E.r. Squibb & Sons, L.L.C. | 2 | $217 |
| Jazz Pharmaceuticals Inc. | 2 | $207 |
| Mylan Specialty L.p. | 2 | $179 |
| Pfizer Pharmaceuticals LLC | 1 | $124 |
| Abbott | 1 | $105 |
| Actelion Pharmaceuticals US, Inc. | 1 | $99 |
| Medtronic | 2 | $73 |
| Genentech USA, Inc. | 1 | $49 |
| AbbVie(2 entities) | 2 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,483 in reported general payments places this provider in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 947 | $509,278 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 450 | $118,881 |
| Fluticasone Propionate HfaFluticasone Propionate | 321 | $75,485 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,405 | $62,367 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 351 | $48,831 |
| SymbicortBudesonide/Formoterol Fumarate | 164 | $40,096 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $23,174 |
| Atrovent HfaIpratropium Bromide | 47 | $22,395 |
| Fluticasone Propionate | 1,375 | $22,394 |
| Wixela InhubFluticasone Propion/Salmeterol | 117 | $18,826 |
| Theophylline ErTheophylline Anhydrous | 284 | $16,904 |
| Montelukast Sodium | 1,054 | $8,341 |
| Cetirizine Hcl | 139 | $2,014 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 26 | $1,488 |
| Dexamethasone | 32 | $935 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat | $605 | $509,278947 claims |
| AstraZenecaSymbicort | $620 | $40,096164 claims |
| GSKBreo Ellipta | $1,210 | $23,17456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Coto Laurel
- Alvaro Aranda RodriguezGuaynabo$725K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Jahaira Serrano DominguezArecibo$102K
- William Villanueva-BosqueArecibo$67K
- Domingo Chardon FelicianoPonce$45K
- Joel Nieves ScharonSan Juan$43K
- George FahedPonce$16K
- Luis Gerena MontanoSan Juan$15K
- Rafael Franjul JuliaoSan Juan$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.